Abbott Laboratories reported third-quarter 2025 results showing continued resilience in its Established Pharmaceuticals Division, which delivered solid growth despite macroeconomic and market headwinds. The division’s performance helped the company reaffirm its full-year earnings and sales guidance.
For the quarter ended September 30, Abbott recorded worldwide sales of approximately $11.37 billion, representing a 6.9% increase year over year on a reported basis and 5.5% growth organically. Excluding COVID-19 testing revenues, organic sales rose 7.5%, supported by expansion across key product lines. Adjusted diluted earnings per share were $1.30, rising 7.4% from the prior year, while GAAP EPS was $0.94.
The Established Pharmaceuticals Division (EPD) generated $1.51 billion in sales, up 7.5% on a reported basis and 7.1% organically. Growth was strongest in emerging markets, where sales climbed 11.1% organically, led by double-digit increases across Asia, Latin America, and the Middle East. Abbott attributed the Division’s momentum to sustained demand for its branded generics portfolio and continued penetration of key therapeutic categories, including cardiovascular and gastroenterology products.
Abbott narrowed its full-year 2025 adjusted EPS guidance to a range of $5.12 to $5.18, reaffirming confidence in double-digit earnings growth at the midpoint. The company noted that while performance in diagnostics was tempered by ongoing pricing pressures in China, strength in both medical devices and pharmaceuticals is expected to sustain its growth trajectory through year-end.
Abbott’s CEO, Robert B. Ford, emphasized that strong execution across businesses—including the pharmaceuticals segment—has allowed the company to maintain stable margins and consistent performance despite uneven market conditions. The company also reaffirmed its long-term strategy centered on emerging-market expansion and innovative product launches across healthcare categories.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!